Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results
March 30, 2021 16:05 ET | Crinetics Pharmaceuticals, Inc.
Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting Phase 1 clinical proof-of-concept data for CRN04894 and CRN04777 expected in 1H 2021 and mid-2021, respectively ...
Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021
March 22, 2021 07:10 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...